Tibotec is changing people's lives and improving public health by fighting infectious diseases worldwide. We are achieving this by delivering innovative therapeutic and diagnostic solutions that provide significant benefits to patients. Tibotec recognizes its responsibility to collaborate in the international response to HIV/AIDS, a challenge which cannot be separated from the fight for gender equality and poverty reduction. For more information on our credo and our giving, please click here. For more information on Tibotec's multi-pronged approach to the HIV/AIDS pandemic in the developing world, please click here.



To find information on people and facilities in the various regions of the world and all of Tibotec's web offerings, see our home page where you can search the global map by region and find links to our disease portals. Or click here to download a copy of the Tibotec Virology Corporate Brochure.



Tibotec R&D is dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. Tibotec was established in 1994 by Rudi Pauwels as a drug discovery laboratory. In 1995, Virco was established as a spin-off to improve the management of HIV/AIDS with innovative, new molecular diagnostic tools for HIV resistance testing that would better inform the treatment decisions made by physicians. In April 2002 Tibotec and Virco were acquired by Johnson & Johnson. Under the leadership of Paul Stoffels, Tibotec evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for Infectious Diseases.

Roger J. Pomerantz, MD, FACP, joined Tibotec on September 1, 2005 as President of Tibotec and Worldwide Therapeutic Area Head of Virology.

Roger J. Pomerantz, President of Tibotec

Recognised as one of the companies at the forefront of HIV research, Tibotec has three novel antiretroviral compounds in phase III clinical development.



For further information on Tibotec's three novel antiretroviral compounds, see:

• TMC114, a protease inhibitor (PI),
• TMC125, a non-nucleoside reverse transcriptase inhibitor (NNRTI),
• TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI).

TMC114 (darunavir) was approved by the United States Food and Drug Administration (FDA) in 2006 and is available in the US through Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.. Darunavir is available in Europe through Tibotec, a division of Janssen-Cilag. TMC125 (etravirine) was approved by the FDA on January 18, 2008 and by the European Commission on the 28th of August, 2008 and is being made available.



TMC120, Tibotec's first NNRTI in clinical development, was licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.



TMC207, a novel anti-TB compound was transferred from Johnson & Johnson PRD to Tibotec for clinical development and is currently in Phase II testing in patients with multi-drug resistant tuberculosis.



In the field of Hepatitis C virus, Tibotec obtained certain ex-US rights to VX-950, an investigational oral inhibitor of hepatitis C virus protease in Phase III development from Vertex.



In addition, Tibotec has internal preclinical HCV drug discovery programs, and has also licensed candidate HCV protease inhibitors from Medivir in a collaboration from which a designated candidate drug, TMC435, has entered phase II.